Moxidectin is safe for dogs when used at approved doses. It has been FDA-approved for heartworm prevention in dogs since 1997 and is found in several widely used products, including topical solutions, monthly chewables, and long-acting injectables. At standard preventive doses, the vast majority of dogs tolerate it well, though certain breeds with a specific genetic mutation need extra caution.
How Moxidectin Works
Moxidectin belongs to a class of drugs called macrocyclic lactones, the same family as ivermectin. It kills parasites by binding to chloride channels in their nerve cells, causing paralysis and death. In mammals, these same channels exist in the brain, but the blood-brain barrier normally prevents moxidectin from reaching them in significant amounts. This is why the drug can destroy heartworm larvae, roundworms, and hookworms circulating in your dog’s body without affecting your dog’s nervous system.
FDA-Approved Products for Dogs
Moxidectin appears in several product types, each with a different formulation and dosing schedule:
- Topical solutions (such as imidacloprid/moxidectin combinations) deliver a minimum dose of 2.5 mg/kg applied to the skin once monthly. These should never be given orally.
- Oral chewables like Simparica Trio combine moxidectin with other active ingredients to prevent heartworm disease while also treating roundworm and hookworm infections and killing fleas and ticks.
- Long-acting injectables (ProHeart 6 and ProHeart 12) provide six or twelve months of heartworm prevention from a single injection given at your veterinarian’s office.
Common Side Effects
Most dogs experience no side effects at all. In a large field study of 583 dogs receiving an injectable moxidectin formulation, about 13% had mild reactions at the injection site, primarily swelling, minor pain, or itching that resolved within 24 hours. Only two dogs out of the entire group (0.3%) had more significant allergic-type reactions involving facial swelling or hives, both of which resolved with treatment.
For oral and topical products, the most commonly reported side effects are vomiting, lethargy, diarrhea, and temporary loss of appetite, typically appearing within a day of administration and clearing quickly.
The MDR1 Gene and Breed Sensitivity
The biggest safety concern with moxidectin involves dogs that carry a mutation in the MDR1 gene (now called ABCB1). This gene controls a protein that acts as a gatekeeper in the blood-brain barrier, pumping drugs back out before they can reach brain tissue. Dogs with two copies of the mutated gene have a faulty gatekeeper, which allows moxidectin and similar drugs to accumulate in the brain and cause neurological problems.
Breeds most likely to carry this mutation include Collies, Australian Shepherds, Shetland Sheepdogs, Old English Sheepdogs, and their mixes. In one documented case, an Australian Shepherd with two mutated copies developed ataxia (loss of coordination), crawling behavior, extreme sensitivity to sounds and touch, and constricted pupils after a single dose of 400 micrograms/kg, a dose far above the standard heartworm prevention level.
The good news is that moxidectin is actually safer than ivermectin for these dogs. It has a lower affinity for the brain receptors that cause toxicity, making it less dependent on a perfectly functioning blood-brain barrier. In studies with ivermectin-sensitive Collies, moxidectin given orally at 30 times the recommended heartworm prevention dose produced no signs of toxicity. The injectable formulation showed no adverse reactions at five times the recommended dose in the same sensitive dogs. By comparison, those same Collies reacted to ivermectin at just 20 times its recommended dose. So while the MDR1 mutation is still a risk factor, moxidectin provides a wider safety margin than the alternatives in this drug class.
If your dog is a breed at risk, a simple DNA test can identify whether they carry the mutation. Dogs that test positive can still use moxidectin-based heartworm preventives at their labeled doses, but your vet should be aware of the results.
Risks With Injectable Formulations
The long-acting injectable versions (ProHeart 6 and ProHeart 12) carry additional considerations. The FDA flagged signals of concern including severe allergic reactions (anaphylaxis), liver disease, autoimmune blood disorders, seizures, and in rare cases, death. Because of this, the FDA requires veterinarians to complete a specific training and certification program before prescribing these products.
Most reactions occur within the first 24 hours after injection, so your vet will likely ask you to monitor your dog closely during that window. These injectables are approved only for healthy dogs. If your dog has a history of allergic reactions, liver problems, immune disorders, or other ongoing health issues, the injectable may not be the right choice.
Accidental Overdose and Toxicity
The most common overdose scenario involves dogs getting into equine deworming paste, which contains moxidectin at concentrations designed for a 1,000-pound horse. In documented cases of accidental exposure, the main signs were generalized tremors and loss of coordination. Importantly, the standard sedative used for seizures (diazepam) tends to work poorly for moxidectin toxicity because of the specific way the drug affects the nervous system.
The prognosis for dogs that accidentally ingest horse dewormer is excellent when the cause is identified quickly and supportive care is provided. If your dog gets into a moxidectin-containing product meant for horses or livestock, getting to a veterinarian immediately gives the best outcome. The key risk factor is the dose relative to body weight: a tube of horse paste delivers a massive overdose to a dog weighing a fraction of what a horse weighs.
How It Compares to Ivermectin
Moxidectin and ivermectin work through the same general mechanism, but structural differences between the two molecules give moxidectin a meaningful safety advantage. Moxidectin binds less strongly to the mammalian brain receptors responsible for neurological side effects. It also interacts differently with the blood-brain barrier’s protective pump. The practical result is a wider margin between an effective dose and a toxic dose, particularly in dogs with the MDR1 gene mutation.
This doesn’t mean ivermectin is dangerous at its labeled heartworm prevention doses. Both drugs are safe when used as directed. But if your dog belongs to a sensitive breed or you’re weighing options with your vet, moxidectin’s broader safety margin is a relevant factor.